AEterna Zentaris (AEZS)
(Delayed Data from NSDQ)
$5.35 USD
-0.05 (-0.93%)
Updated Jul 26, 2024 02:51 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
AEZS 5.35 -0.05(-0.93%)
Will AEZS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AEZS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AEZS
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
AEZS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates
Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates
Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug
Other News for AEZS
Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
Mannatech Announces Appointment of James Clavijo as Chief Financial Officer
Aeterna Zentaris Release: A Technical Glitch?
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
Aeterna Zentaris Wraps Up Key Pediatric Trial